Company profile for Jiangsu Simcere Pharmaceutical

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are rapidly transitioning to an innovation and R&D-driven pharmaceutical company, leveraging our leading manufacturing and commercial capabilities to achieve our mission of “providing today’s patients with medicines of the future” . We have established three R&D centers in Nanjing, Shanghai and Boston, respectively. With the approval of the Ministry of Science and Technology, we have also established a national key la...
We are rapidly transitioning to an innovation and R&D-driven pharmaceutical company, leveraging our leading manufacturing and commercial capabilities to achieve our mission of “providing today’s patients with medicines of the future” . We have established three R&D centers in Nanjing, Shanghai and Boston, respectively. With the approval of the Ministry of Science and Technology, we have also established a national key laboratory of translational medicine and innovative pharmaceuticals .

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
699-18 Xuanwu Avenue Nanjing
Telephone
Telephone
025-85566666
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/simceres-il-2-mutant-fusion-protein-sim0278-entered-phase-ii-clinical-trial-stage-302609998.html

PR NEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/10/16/3167884/0/en/NextCure-and-Simcere-Zaiming-Announce-Expansion-of-Ongoing-Phase-1-Trial-of-SIM0505-CDH6-ADC-into-the-United-States.html

GLOBENEWSWIRE
16 Oct 2025

https://www.globenewswire.com/news-release/2025/09/22/3153620/0/en/Global-expansion-of-Idorsia-s-QUVIVIQ-continues-as-Simcere-launches-in-China.html

GLOBENEWSWIRE
22 Sep 2025

https://www.globenewswire.com/news-release/2025/07/09/3112607/0/en/Connect-Biopharma-s-Exclusive-Licensee-in-China-Simcere-Pharmaceutical-Announced-Submission-of-its-New-Drug-Application-for-Rademikibart-for-the-Treatment-of-Atopic-Dermatitis-in-C.html

GLOBENEWSWIRE
09 Jul 2025

https://www.prnewswire.com/news-releases/simcere-zaiming-announces-first-patient-dosed-in-the-us-in-a-phase-1-trial-of-trispecific-antibody-sim0500-in-patients-with-relapsedrefractory-multiple-myeloma-302485872.html

PR NEWSWIRE
18 Jun 2025

https://www.biospace.com/business/nextcure-joins-china-adc-gold-rush-with-745m-simcere-deal

BIOSPACE
17 Jun 2025

ABOUT THIS PAGE

Contact Jiangsu Simcere Pharmaceutical and get a quotation

Jiangsu Simcere Pharmaceutical is a supplier offers 2 products (APIs, Excipients or Intermediates).

Find a price of Iguratimod bulk with JDMF offered by Jiangsu Simcere Pharmaceutical

Find a price of Dioctahedral smectite bulk offered by Jiangsu Simcere Pharmaceutical

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty